Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. was established in 1978. It is a comprehensive pharmaceutical enterprise specializing in drug research and development, production and operation. It was successfully listed on the A-share main board of the Shanghai Stock Exchange on July 2, 2014 ( Stock code: 603168).

In October 2020, it successfully acquired Taizhou Obstetrics and Gynecology Hospital affiliated to Nantong University, officially entering the high-quality development of "pharmaceutical + medical care", and becoming a big health enterprise focusing on ophthalmology and obstetrics and gynecology. .

The company has subsidiaries such as Zhejiang Shapu Aisi Pharmaceutical Sales Co., Ltd., Zhejiang Shapu Aisi Pharmacy Chain Co., Ltd., Taizhou Women and Children's Hospital Co., Ltd.

Work hard to achieve strength, and strength creates excellence. Since its establishment, the company has passed the "High-tech Enterprise" certification for four consecutive times, and has been successively rated as "Key High-tech Enterprise of the National Torch Plan" and "Zhejiang Province Standard Innovation Enterprise". It has also been awarded "other sciences in China's chemical pharmaceutical industry" many times. Excellent product brand for drug use", "OTC excellent product brand for Chinese chemical pharmaceutical industry", "Social Responsibility Targeted Poverty Alleviation Award" and other honors.

The company's main products, the anti-cataract, national second-class ophthalmic new drug "Shapuaisi" eye drops and the anti-glaucoma new drug "Daliang" eye drops were included in the "National Torch Plan Project". In addition, the company also has subdivided therapeutic areas such as antimicrobial drugs (cephalosporins), antimicrobial drugs (quinolones), water, electrolytes and acid-base balance drugs, including large-volume injections, oral solutions, tablets ( More than ten kinds of chemical preparations and traditional Chinese medicine preparation products, including cephalosporins), hard capsules (including cephalosporins), etc.

Social responsibility, public welfare first. Shapu Aisi actively assumes social responsibility and devotes himself to public welfare undertakings. In recent years, the company has successively carried out a series of large-scale public welfare actions such as "Finishing China", "Concentric Circle·Government Consciousness", "Welcome a Century, and Performing Bailisha Pharmaceutical Charity to the Original Intention", and established the "Public Love Tongxin Charity Special Fund", etc. Give back to the society with practical actions, guide positive energy to spread, and continuously contribute to the development of China's public welfare undertakings.